Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pc-dac insulin
- Development stage
- Preclinical
- Lead developer
- ConjuChem
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
PC-DAC insulin is a long-acting insulin product developed using ConjuChem's proprietary Drug Affinity Complex (PC-DAC) technology. This technology creates a conjugate between insulin and albumin, resulting in a half-life up to 30 times longer than native insulin with bioactivity lasting more than 12 hours. It's designed to provide better glycemic control with fewer injections for diabetes patients.
- Brand names
- PC-DAC™: Insulin
- Other names
- PC-DAC: InsulinPC-Insulininsulin receptor-peptide-albumin conjugatePC-DAC Insulin
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on pc-dac insulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pc-dac insulin.